Advertisement

Journal of Neurology

, Volume 264, Issue 3, pp 541–553 | Cite as

Reduced serum myostatin concentrations associated with genetic muscle disease progression

  • Peter M. Burch
  • Oksana Pogoryelova
  • Joe Palandra
  • Richard Goldstein
  • Donald Bennett
  • Lori Fitz
  • Michela Guglieri
  • Chiara Marini Bettolo
  • Volker Straub
  • Teresinha Evangelista
  • Hendrik Neubert
  • Hanns Lochmüller
  • Carl Morris
Original Communication

Abstract

Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC–MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.

Keywords

Myostatin Neuromuscular disease Biomarker Mass spectrometry 

Notes

Acknowledgements

This work was supported by the EU funded projects BIO-NMD (No.241665), Neuromics (No. 305121) and RD-Connect (305444) and by the Medical Research Council (MRC) Centre for Neuromuscular Diseases Biobanks (Newcastle) which are part of EuroBioBank; we are grateful to Dan Cox and Mojgan Reza for technical support at the biobank and Karen Bettinson for support with phenotype data. We thank the Jain foundation for providing the LGMD2B patient samples and their helpful comments. We thank the Predictive Safety Testing Consortium of the Critical Path Institute for their contribution of healthy control serum samples.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical standards

All studies involving human samples were conducted in accordance with the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects and in accordance with a protocol which was approved by the local Institutional Review Board. All animals were handled in compliance with the NIH and institutional guidelines that were approved by the Institutional Animal Care and Use Committee Pfizer, Inc (Groton, CT, USA).

Supplementary material

415_2016_8379_MOESM1_ESM.docx (211 kb)
Supplementary material 1 (DOCX 210 kb)

References

  1. 1.
    Aartsma-Rus A, Ferlini A, Vroom E (2014) Biomarkers and surrogate endpoints in Duchenne: meeting report. Neuromuscul Disord NMD 24:743–745CrossRefPubMedGoogle Scholar
  2. 2.
    Anaya-Segura MA, Garcia-Martinez FA, Montes-Almanza LA, Diaz BG, Avila-Ramirez G, Alvarez-Maya I, Coral-Vazquez RM, Mondragon-Teran P, Escobar-Cedillo RE, Garcia-Calderon N, Vazquez-Cardenas NA, Garcia S, Lopez-Hernandez LB (2015) Non-invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules (Basel, Switzerland) 20:11154–11172CrossRefGoogle Scholar
  3. 3.
    Awano H, Takeshima Y, Okizuka Y, Saiki K, Yagi M, Matsuo M (2008) Wide ranges of serum myostatin concentrations in duchenne muscular dystrophy patients. Clin Chim Acta 391:115–117CrossRefPubMedGoogle Scholar
  4. 4.
    Ayoglu B, Chaouch A, Lochmüller H, Politano L, Bertini E, Spitali P, Hiller M, Niks EH, Gualandi F, Pontén F, Bushby K, Aartsma-Rus A, Schwartz E, Le Priol Y, Straub V, Uhlen M, Cirak S, 't Hoen PA, Muntoni F, Ferlini A, Schwenk JM, Nilsson P, Al-Khalili Szigyarto C (2014) Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO mol med 6:918–936CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bergen HR 3rd, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, Khosla S, LeBrasseur NK (2015) Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle 5:21CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418–421CrossRefPubMedGoogle Scholar
  7. 7.
    Broccolini A, Mirabella M (2015) Hereditary inclusion-body myopathies. Biochim Biophys Acta 1852:644–650CrossRefPubMedGoogle Scholar
  8. 8.
    Burch PM, Pogoryelova O, Goldstein R, Bennett D, Guglieri M, Straub V, Bushby K, Lochmuller H, Morris C (2015) Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. J Neuromuscul Dis 2:241–255CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Davies KE (1997) Challenges in Duchenne muscular dystrophy. Neuromuscul Disord NMD 7:482–486CrossRefPubMedGoogle Scholar
  10. 10.
    Flanigan KM (2012) The muscular dystrophies. Semin Neurol 32:255–263CrossRefPubMedGoogle Scholar
  11. 11.
    Gallardo E, Saenz A, Illa I (2011) Limb-girdle muscular dystrophy 2A. Hand Clin Neurol 101:97–110CrossRefGoogle Scholar
  12. 12.
    Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK, Furlong P, Gordish-Dressman H, Hache L, Henricson E, Hoffman EP, Kobayashi YM, Lorts A, Mah JK, McDonald C, Mehler B, Nelson S, Nikrad M, Singer B, Steele F, Sterling D, Sweeney HL, Williams S, Gold L (2015) Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 112:7153–7158CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y (2002) The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277:40735–40741CrossRefPubMedGoogle Scholar
  14. 14.
    Hill JJ, Qiu Y, Hewick RM, Wolfman NM (2003) Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol (Baltimore, Md) 17:1144–1154CrossRefGoogle Scholar
  15. 15.
    Joulia-Ekaza D, Cabello G (2007) The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol 7:310–315CrossRefPubMedGoogle Scholar
  16. 16.
    Lakshman KM, Bhasin S, Corcoran C, Collins-Racie LA, Tchistiakova L, Forlow SB, St Ledger K, Burczynski ME, Dorner AJ, Lavallie ER (2009) Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol 302:26–32CrossRefPubMedGoogle Scholar
  17. 17.
    Laval SH, Bushby KM (2004) Limb-girdle muscular dystrophies–from genetics to molecular pathology. Neuropathol Appl Neurobiol 30:91–105CrossRefPubMedGoogle Scholar
  18. 18.
    Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK (2015) A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther J Am Soc Gene Ther 23:192–201CrossRefGoogle Scholar
  19. 19.
    Mendias CL, Lynch EB, Davis ME, Enselman ERS, Harning JA, DeWolf PD, Makki TA, Bedi A (2013) Changes in circulating biomarkers of muscle atrophy, inflammation and cartilage turnover in patients undergoing anterior cruciate ligament reconstruction and rehabilitation. Am J Sports Med 41:1819–1826CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Morine KJ, Bish LT, Pendrak K, Sleeper MM, Barton ER, Sweeney HL (2010) Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One 5:e9176CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K (2008) Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J Off Publ Fed Am Soc Exp Biol 22:477–487Google Scholar
  22. 22.
    Nigro G, Papa AA, Politano L (2012) The heart and cardiac pacing in Steinert disease. Acta Myologica 31:110–116PubMedPubMedCentralGoogle Scholar
  23. 23.
    Nigro V, Savarese M (2014) Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol Myopathies Card Off J Mediterr Soc Myol 33:1–12 (edited by the Gaetano Conte Academy for the study of striated muscle diseases) Google Scholar
  24. 24.
    Ozawa E, Hagiwara Y, Yoshida M (1999) Creatine kinase, cell membrane and Duchenne muscular dystrophy. Mol Cell Biochem 190:143–151CrossRefPubMedGoogle Scholar
  25. 25.
    Palandra J, Quazi A, Fitz L, Rong H, Morris C, Neubert H (2016) Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS. Proteom Clin Appl 10:597–604CrossRefGoogle Scholar
  26. 26.
    Partridge TA (2013) The mdx mouse model as a surrogate for Duchenne muscular dystrophy. FEBS J 280:4177–4186CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Phillips MF, Quinlivan RC, Edwards RH, Calverley PM (2001) Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 164:2191–2194CrossRefPubMedGoogle Scholar
  28. 28.
    Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, DeVries A, Rauchhaus P, Crowther D, Alesci S, Yaworsky P, Gilbert F, Redpath TW, Brady J, Fearon KC, Reid DM, Greig CA, Wackerhage H (2011) Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol Ser A Biol Sci Med Sci 66:620–626CrossRefGoogle Scholar
  29. 29.
    Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, Manzur AY, Muntoni F (2016) The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87:149–155PubMedGoogle Scholar
  30. 30.
    Ruegg UT (2013) Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 26:577–584CrossRefPubMedGoogle Scholar
  31. 31.
    Saremi A, Gharakhanloo R, Sharghi S, Gharaati MR, Larijani B, Omidfar K (2010) Effects of oral creatine and resistance training on serum myostatin and GASP-1. Mol Cell Endocrinol 317:25–30CrossRefPubMedGoogle Scholar
  32. 32.
    Sartori R, Gregorevic P, Sandri M (2014) TGFbeta and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends Endocrinol Metab Tem 25:464–471CrossRefPubMedGoogle Scholar
  33. 33.
    Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Eng J Med 350:2682–2688CrossRefGoogle Scholar
  34. 34.
    Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR (2014) Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50:250–256CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Szulc P, Schoppet M, Goettsch C, Rauner M, Dschietzig T, Chapurlat R, Hofbauer LC (2012) Endocrine and clinical correlates of myostatin serum concentration in men–the STRAMBO study. J Clin Endocrinol Metab 97:3700–3708CrossRefPubMedGoogle Scholar
  36. 36.
    Thornton CA (2014) Myotonic dystrophy. Neurologic clinics 32:705–719 (viii) CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Tobin JF, Celeste AJ (2005) Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseases. Curr Opin Pharmacol 5:328–332CrossRefPubMedGoogle Scholar
  38. 38.
    Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR (2008) A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561–571CrossRefPubMedGoogle Scholar
  39. 39.
    Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz P, Thompson TB, Wagers AJ, Lee RT (2016) Biochemistry and biology of GDF11 and myostatin: similarities, differences, and questions for future investigation. Circ Res 118:1125–1142CrossRefPubMedGoogle Scholar
  40. 40.
    Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, Kress W, Muller-Reible C, Vorgerd M, Urban P, Schrank B, Deschauer M, Schlotter-Weigel B, Kohnen R, Lochmuller H (2013) Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 8:26CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wang LH, Tawil R (2016) Facioscapulohumeral dystrophy. Curr Neurol Neurosci Rep 16:66CrossRefPubMedGoogle Scholar
  42. 42.
    White TA, LeBrasseur NK (2014) Myostatin and sarcopenia: opportunities and challenges—a mini-review. Gerontology 60:289–293CrossRefPubMedGoogle Scholar
  43. 43.
    Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF (2002) Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J Nutr Health Aging 6:343–348PubMedGoogle Scholar
  44. 44.
    Zaharieva IT, Calissano M, Scoto M, Preston M, Cirak S, Feng L, Collins J, Kole R, Guglieri M, Straub V, Bushby K, Ferlini A, Morgan JE, Muntoni F (2013) Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS One 8:e80263CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Peter M. Burch
    • 1
  • Oksana Pogoryelova
    • 2
  • Joe Palandra
    • 3
  • Richard Goldstein
    • 1
  • Donald Bennett
    • 4
  • Lori Fitz
    • 4
  • Michela Guglieri
    • 2
  • Chiara Marini Bettolo
    • 2
  • Volker Straub
    • 2
  • Teresinha Evangelista
    • 2
  • Hendrik Neubert
    • 3
  • Hanns Lochmüller
    • 2
  • Carl Morris
    • 4
    • 5
  1. 1.Worldwide Research and DevelopmentPfizer Inc.GrotonUSA
  2. 2.John Walton Muscular Dystrophy Research Centre, Institute of Genetic MedicineNewcastle UniversityNewcastle upon TyneUK
  3. 3.Worldwide Research and DevelopmentPfizer Inc.AndoverUSA
  4. 4.Worldwide Research and DevelopmentPfizer Inc.CambridgeUSA
  5. 5.Solid BiosciencesCambridgeUSA

Personalised recommendations